Trial Profile

Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golimumab (Primary)
Indications Ulcerative colitis
Focus Pharmacokinetics; Therapeutic Use
Acronyms GOLILOR

Most Recent Events

11 Mar 2022 Status changed from recruiting to completed.
07 Jan 2022 Planned primary completion date changed from 30 Oct 2021 to 30 May 2022.
05 Jan 2021 Planned End Date changed from 30 May 2021 to 30 May 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com